Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and

@article{Fisher1996SequentialMA,
  title={Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and },
  author={Bernard Fisher and James Dignam and Eleftherios P Mamounas and J. P. Costantino and Donald Lawrence Wickerham and Carol Redmond and Norman Wolmark and Nikolay V. Dimitrov and David M. Bowman and Andrew Glass and James Norman Atkins and Neil Abramson and Carl M. Sutherland and Bernard S Aron and Richard G. Margolese},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 7},
  pages={1982-92}
}
PURPOSE To compare sequential methotrexate (M) and fluorouracil (F) (M-->F) with surgery (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-13) and cyclophosphamide (C), M, and F with M-->F (NSABP B-19), in patients with estrogen receptor (ER)-negative tumors and negative axillary nodes. PATIENTS AND METHODS A total of 760 patients were randomized to B-13; 1,095 patients with the same eligibility requirements were randomized to B-19. Disease-free survival (DFS), distant disease… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

Similar Papers

Loading similar papers…